InvestorsHub Logo
Followers 31
Posts 1587
Boards Moderated 0
Alias Born 01/27/2011

Re: None

Friday, 12/13/2013 3:02:28 PM

Friday, December 13, 2013 3:02:28 PM

Post# of 796
Brean Capital recently issued an upgraded price target from $9 to $11 a share. With confirmation of AZEDRA clinical progression, Phase 1 success in MIP -1404 and the upcoming catalyst dates discussed, further analyst upgrades could follow very soon.